ATE203539T1 - Gehinderte n-oxid ester von rapamycin und ihre verwendung als arzneimittel - Google Patents

Gehinderte n-oxid ester von rapamycin und ihre verwendung als arzneimittel

Info

Publication number: ATE203539T1
Authority: AT; Austria
Prior art keywords: hinderned; rapamycin; medicinal products; oxide esters; alkyl
Prior art date: 1994-11-28

Application number

AT95941467T

Other languages

English (en)

Inventor

Frances Christy Nelson

Guy Alan Schiehser

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-28

Filing date

1995-11-22

Publication date

2001-08-15

1995-11-22 Application filed by American Home Prod filed Critical American Home Prod

2001-08-15 Application granted granted Critical

2001-08-15 Publication of ATE203539T1 publication Critical patent/ATE203539T1/de

Links

229940126601 medicinal product Drugs 0.000 title 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
229960002930 sirolimus Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
230000000843 anti-fungal effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
229940121375 antifungal agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT95941467T 1994-11-28 1995-11-22 Gehinderte n-oxid ester von rapamycin und ihre verwendung als arzneimittel ATE203539T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/345,972 US5491231A (en)	1994-11-28	1994-11-28	Hindered N-oxide esters of rapamycin
PCT/US1995/015318 WO1996016967A1 (en)	1994-11-28	1995-11-22	Hindered n-oxide esters of rapamycin and their use as medicaments

Publications (1)

Publication Number	Publication Date
ATE203539T1 true ATE203539T1 (de)	2001-08-15

Family

ID=23357367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95941467T ATE203539T1 (de)	1994-11-28	1995-11-22	Gehinderte n-oxid ester von rapamycin und ihre verwendung als arzneimittel

Country Status (18)

Country	Link
US (5)	US5491231A (de)
EP (1)	EP0794955B1 (de)
JP (1)	JPH10509977A (de)
KR (1)	KR100377278B1 (de)
AT (1)	ATE203539T1 (de)
AU (1)	AU712998B2 (de)
BR (1)	BR9509825A (de)
CA (1)	CA2205577A1 (de)
DE (1)	DE69521907T2 (de)
DK (1)	DK0794955T3 (de)
ES (1)	ES2158959T3 (de)
FI (1)	FI972240A7 (de)
GR (1)	GR3036712T3 (de)
HU (1)	HUT77139A (de)
MX (1)	MX9703893A (de)
NZ (1)	NZ297661A (de)
PT (1)	PT794955E (de)
WO (1)	WO1996016967A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW401275B (en)	1995-09-25	2000-08-11	Basf Ag	Compositions and methods of controlling harmful fungi
US5780462A (en) *	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US5922730A (en) *	1996-09-09	1999-07-13	American Home Products Corporation	Alkylated rapamycin derivatives
US5916465A (en) *	1997-10-16	1999-06-29	Tweco Products, Inc.	Torch
US6015809A (en) *	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
US6331547B1 (en)	1999-08-18	2001-12-18	American Home Products Corporation	Water soluble SDZ RAD esters
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US20050002986A1 (en) *	2000-05-12	2005-01-06	Robert Falotico	Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en)	2000-05-12	2012-08-07	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) *	2000-05-12	2007-11-27	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
JP2004507465A (ja)	2000-08-11	2004-03-11	ワイス	エストロゲン受容体陽性癌腫の治療方法
ATE411321T1 (de)	2000-09-19	2008-10-15	Wyeth Corp	Wasserlösliche rapamycin-ester
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
CA2424029C (en) *	2000-09-29	2008-01-29	Cordis Corporation	Coated medical devices
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en)	2000-10-02	2002-08-27	Wyeth	Ethers of 7-desmethlrapamycin
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
PT1478648E (pt) *	2002-02-01	2014-07-15	Ariad Pharma Inc	Compostos contendo fósforo e suas utilizações
AR040693A1 (es)	2002-07-30	2005-04-13	Wyeth Corp	Formulaciones parenterales
WO2004060283A2 (en)	2002-12-16	2004-07-22	Nitromed, Inc.	Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
WO2004069159A2 (en) *	2003-01-27	2004-08-19	Endocyte, Inc.	Vitamin receptor binding drug delivery conjugates
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
PL1735321T3 (pl) *	2004-04-14	2009-04-30	Wyeth Corp	Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
CN1946852A (zh) *	2004-04-27	2007-04-11	惠氏公司	利用雷帕霉素特异性甲基化酶标记雷帕霉素
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
CN101098854B (zh)	2004-07-23	2012-12-05	恩多塞特公司	二价连接体及其轭合物
KR20070070184A (ko) *	2004-10-28	2007-07-03	와이어쓰	자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
GB0503936D0 (en) *	2005-02-25	2005-04-06	San Raffaele Centro Fond	Method
CN101175757B (zh) *	2005-03-16	2012-11-14	恩多塞特公司	蝶酸及其缀合物的合成和纯化
RU2423381C2 (ru) *	2005-07-25	2011-07-10	Трабьон Фармасьютикалз, Инк.	Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
BRPI0615354A2 (pt) *	2005-08-19	2011-05-17	Endocyte, Inc.	conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
EP1942937A1 (de)	2005-11-04	2008-07-16	Wyeth	Antitumor-kombinationen mit mtor-hemmer, herceptin und/oder hki-272
US20070142422A1 (en) *	2005-12-20	2007-06-21	Wyeth	Control of CCI-779 dosage form stability through control of drug substance impurities
US7678901B2 (en) *	2006-02-28	2010-03-16	Wyeth	Rapamycin analogs containing an antioxidant moiety
US20080051691A1 (en) *	2006-08-28	2008-02-28	Wyeth	Implantable shunt or catheter enabling gradual delivery of therapeutic agents
JP2010509400A (ja) *	2006-11-14	2010-03-25	アリアド・ファーマシューティカルズ・インコーポレイテッド	経口処方組成物
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US20100104626A1 (en)	2007-02-16	2010-04-29	Endocyte, Inc.	Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en)	2007-03-14	2008-09-18	Endocyte, Inc.	Binding ligand linked drug delivery conjugates of tubulysins
TW200901989A (en)	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9877965B2 (en)	2007-06-25	2018-01-30	Endocyte, Inc.	Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh)	2007-06-25	2014-12-10	恩多塞特公司	含有亲水性间隔区接头的共轭物
JP2010532764A (ja) *	2007-07-06	2010-10-14	トゥルビオン・ファーマシューティカルズ・インコーポレーテッド	Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
US20100048913A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
RU2531754C2 (ru) *	2008-04-11	2014-10-27	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US	Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
CN102686600A (zh)	2009-02-05	2012-09-19	托凯药业股份有限公司	甾体cyp17抑制剂/抗雄激素物质的新型药物前体
JP2013509444A (ja)	2009-10-30	2013-03-14	アリアド・ファーマシューティカルズ・インコーポレイテッド	がんの治療方法及び治療用組成物
WO2015161139A1 (en)	2014-04-16	2015-10-22	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
EP2542670A2 (de)	2010-03-05	2013-01-09	President and Fellows of Harvard College	Zusammensetzungen aus induzierten dentritischen zellen und ihre verwendung
RU2585489C2 (ru)	2010-04-27	2016-05-27	Рош Гликарт Аг	КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2532740A1 (de)	2011-06-11	2012-12-12	Michael Schmück	Antigenspezifische CD4+ und CD8+ zentrale Gedächtnis-T-Zellpräparate für adoptive T-Zelltherapie
US10080805B2 (en)	2012-02-24	2018-09-25	Purdue Research Foundation	Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en)	2012-03-29	2014-03-20	Endocyte, Inc.	Processes for preparing tubulysin derivatives and conjugates thereof
WO2014059295A1 (en)	2012-10-12	2014-04-17	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
BR112015008365A2 (pt)	2012-10-16	2017-07-04	Endocyte Inc	composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
US20150258127A1 (en)	2012-10-31	2015-09-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
RU2015137617A (ru)	2013-03-14	2017-04-18	Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер	Агенты, подавляющие андрогенные рецепторы, и их применение
CN105636594A (zh)	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
EP3089737B1 (de)	2013-12-31	2021-11-03	Rapamycin Holdings, LLC	Orale rapamycinnanopartikelzubereitungen und verwendung
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
CA2943609A1 (en)	2014-03-27	2015-10-01	The Brigham And Women's Hospital, Inc.	Metabolically-activated drug conjugates to overcome resistance in cancer therapy
EP3148564B1 (de)	2014-06-02	2020-01-08	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur immunmodulation
CN105461738B (zh)	2014-06-03	2019-03-08	中国人民解放军军事医学科学院毒物药物研究所	一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
CN113620978A (zh)	2014-09-11	2021-11-09	加利福尼亚大学董事会	mTORC1抑制剂
WO2017029391A1 (en)	2015-08-20	2017-02-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method for treating cancer
US20210154372A1 (en)	2017-05-15	2021-05-27	C.R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
WO2019002168A1 (en)	2017-06-26	2019-01-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
EP3652306A1 (de)	2017-07-13	2020-05-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur erhöhung der expansion und der immunosuppressiven kapazität einer population von cd8+cd45rclow/-tregs
MX2020011565A (es)	2018-05-01	2021-01-29	Revolution Medicines Inc	Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
IL312291A (en)	2018-05-01	2024-06-01	Revolution Medicines Inc	C-26-linked rapamycin analogs as MTOR inhibitors
AU2019310040A1 (en)	2018-07-23	2021-02-11	Enclear Therapies, Inc.	Methods of treating neurological disorders
AU2019310039A1 (en)	2018-07-23	2021-02-18	Enclear Therapies, Inc.	Methods of treating neurological disorders
EP3849545A1 (de)	2018-09-10	2021-07-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von neurofibromatose
EP3880266B1 (de)	2018-11-14	2025-05-07	Lutonix, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung auf modifizierter vorrichtungsoberfläche
WO2020163594A1 (en)	2019-02-07	2020-08-13	The Regents Of The University Of California	Immunophilin binding agents and uses thereof
EP3952937A1 (de)	2019-04-08	2022-02-16	Bard Peripheral Vascular, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung auf modifizierter vorrichtungsoberfläche
AU2020271894A1 (en)	2019-04-11	2021-12-02	Enclear Therapies, Inc.	Methods of amelioration of cerebrospinal fluid and devices and systems therefor
US12329930B2 (en)	2020-09-29	2025-06-17	Enclear Therapies, Inc.	Subarachnoid fluid management method and system
WO2023288046A1 (en)	2021-07-15	2023-01-19	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
CA3256390A1 (en)	2022-05-25	2023-11-30	Revolution Medicines, Inc.	CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
US20260000658A1 (en)	2022-07-06	2026-01-01	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of proliferative glomerulonephritis
EP4565217A1 (de)	2022-08-04	2025-06-11	Institut National de la Santé et de la Recherche Médicale	Verfahren zur behandlung lymphoproliferativer erkrankungen
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3205234A (en) *	1961-06-30	1965-09-07	Upjohn Co	Nu-oxides of pyridyl ketone omicron-hydrocarbonoximes
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US4316885A (en) *	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) *	1981-11-19	1983-03-01	Ayerst, Mckenna & Harrison Inc.	Antibiotic AY24,668 and process of preparation
US4650803A (en) *	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023264A (en) *	1990-07-16	1991-06-11	American Home Products Corporation	Rapamycin oximes
US5023263A (en) *	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
US5023262A (en) *	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
US5221670A (en) *	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
US5130307A (en) *	1990-09-28	1992-07-14	American Home Products Corporation	Aminoesters of rapamycin
US5233036A (en) *	1990-10-16	1993-08-03	American Home Products Corporation	Rapamycin alkoxyesters
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5120842A (en) *	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
IL101353A0 (en) *	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
US5100883A (en) *	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en) *	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5194447A (en) *	1992-02-18	1993-03-16	American Home Products Corporation	Sulfonylcarbamates of rapamycin
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) *	1991-05-07	1992-04-07	American Home Products Corporation	Reduction products of rapamycin
US5138051A (en) *	1991-08-07	1992-08-11	American Home Products Corporation	Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) *	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5169851A (en) *	1991-08-07	1992-12-08	American Home Products Corporation	Rapamycin analog as immunosuppressants and antifungals
US5151413A (en) *	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) *	1992-03-05	1993-01-05	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5260300A (en) *	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
US5373014A (en) *	1993-10-08	1994-12-13	American Home Products Corporation	Rapamycin oximes
US5385909A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Heterocyclic esters of rapamycin
US5385908A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Hindered esters of rapamycin
US5385910A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Gem-distributed esters of rapamycin

1994
- 1994-11-28 US US08/345,972 patent/US5491231A/en not_active Expired - Lifetime
1995
- 1995-05-24 US US08/450,769 patent/US5521194A/en not_active Expired - Lifetime
- 1995-05-24 US US08/448,843 patent/US5559122A/en not_active Expired - Lifetime
- 1995-05-24 US US08/449,167 patent/US5508290A/en not_active Expired - Lifetime
- 1995-05-24 US US08/449,168 patent/US5508285A/en not_active Expired - Lifetime
- 1995-11-22 AU AU42877/96A patent/AU712998B2/en not_active Ceased
- 1995-11-22 HU HU9701851A patent/HUT77139A/hu unknown
- 1995-11-22 DK DK95941467T patent/DK0794955T3/da active
- 1995-11-22 EP EP95941467A patent/EP0794955B1/de not_active Expired - Lifetime
- 1995-11-22 NZ NZ297661A patent/NZ297661A/xx unknown
- 1995-11-22 MX MX9703893A patent/MX9703893A/es not_active IP Right Cessation
- 1995-11-22 KR KR1019970703519A patent/KR100377278B1/ko not_active Expired - Fee Related
- 1995-11-22 PT PT95941467T patent/PT794955E/pt unknown
- 1995-11-22 DE DE69521907T patent/DE69521907T2/de not_active Expired - Fee Related
- 1995-11-22 WO PCT/US1995/015318 patent/WO1996016967A1/en not_active Ceased
- 1995-11-22 JP JP8518953A patent/JPH10509977A/ja not_active Withdrawn
- 1995-11-22 AT AT95941467T patent/ATE203539T1/de not_active IP Right Cessation
- 1995-11-22 BR BR9509825A patent/BR9509825A/pt active Search and Examination
- 1995-11-22 CA CA002205577A patent/CA2205577A1/en not_active Abandoned
- 1995-11-22 ES ES95941467T patent/ES2158959T3/es not_active Expired - Lifetime
1997
- 1997-05-27 FI FI972240A patent/FI972240A7/fi unknown
2001
- 2001-09-26 GR GR20010401569T patent/GR3036712T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5508290A (en)	1996-04-16
HUT77139A (hu)	1998-03-02
US5559122A (en)	1996-09-24
DK0794955T3 (da)	2001-09-24
AU4287796A (en)	1996-06-19
US5508285A (en)	1996-04-16
PT794955E (pt)	2001-12-28
FI972240A0 (fi)	1997-05-27
WO1996016967A1 (en)	1996-06-06
JPH10509977A (ja)	1998-09-29
KR100377278B1 (ko)	2003-10-04
GR3036712T3 (en)	2001-12-31
ES2158959T3 (es)	2001-09-16
BR9509825A (pt)	1997-09-30
DE69521907T2 (de)	2001-11-29
US5491231A (en)	1996-02-13
DE69521907D1 (de)	2001-08-30
EP0794955B1 (de)	2001-07-25
AU712998B2 (en)	1999-11-18
FI972240A7 (fi)	1997-05-27
US5521194A (en)	1996-05-28
NZ297661A (en)	2000-01-28
MX9703893A (es)	1997-08-30
HK1002281A1 (en)	1998-08-14
EP0794955A1 (de)	1997-09-17
CA2205577A1 (en)	1996-06-06

Legal Events

Date	Code	Title	Description
2001-11-15	UEP	Publication of translation of european patent specification
2004-08-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE203539T1 (de)	2001-08-15	Gehinderte n-oxid ester von rapamycin und ihre verwendung als arzneimittel
ATE181076T1 (de)	1999-06-15	Gehinderte ester von rapamycin und ihre verwendung als arzneimittel
ATE199555T1 (de)	2001-03-15	Heterocyclische ester von rapamycin und sie enthaltende pharmazeutische zusammensetzungen
DE69302249D1 (de)	1996-05-23	Prolinderivat von Rapamycin, seine Herstellung und Verwendung
PL326159A1 (en)	1998-08-31	Heterocyclic fungicides
ES2093860T3 (es)	1997-01-01	Nuevos derivados de arilcicloalquilo, su produccion y su uso.
EP0893446A4 (de)	1999-01-27
ES2096941T3 (es)	1997-03-16	27-hidroxirrapamicina y derivados de la misma.
ATE81857T1 (de)	1992-11-15	Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
YU248190A (sh)	1992-12-21	Fungicidi
DE69311123D1 (de)	1997-07-03	Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe
AU574204B2 (en)	1988-06-30	5-amino-1-phenylpyrazole derivatives
DE68911006D1 (de)	1994-01-13	Pharmakologisch-aktive Alkylthiobenzimidazol-Derivate und Verfahren zu deren Herstellung.
DE69509231D1 (de)	1999-05-27	3-substituierte pyridinverbindungen und deren derivate als herbizide
DE69031730D1 (de)	1998-01-02	Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
DE69305659D1 (de)	1996-12-05	17-Phenyl-substituierte Steroide mit cardiotonischer Wirksamkeit
ATE138932T1 (de)	1996-06-15	17-(pyridazin-n-oxyd)-substituierte steroide mit cardiotonischer wirksamkeit
GR1001405B (el)	1993-11-30	Ενώσεις 2-πιπεραζινόνης και η παραγωγή και η χρησιμοποίηση αυτών.